Restoring carbapenem efficacy: a novel carbapenem companion targeting metallo-β-lactamases in carbapenem-resistant Enterobacterales | Zendy

Nicola Ooi | Zendy; Victoria E. Lee | Zendy; Nathan Chalam-Judge | Zendy; Rebecca Newman | Zendy; Andrew J. Wilkinson | Zendy; Ian R. Cooper | Zendy; David Orr | Zendy; Sally Lee | Zendy; Victoria J. Savage | Zendy

Open Access

Restoring carbapenem efficacy: a novel carbapenem companion targeting metallo-β-lactamases in carbapenem-resistant Enterobacterales

Author(s) -

Nicola Ooi,

Victoria E. Lee,

Nathan Chalam-Judge,

Rebecca Newman,

Andrew J. Wilkinson,

Ian R. Cooper,

David Orr,

Sally Lee,

Victoria J. Savage

Publication year - 2020

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkaa455

Subject(s) - meropenem , carbapenem , microbiology and biotechnology , antimicrobial , escherichia coli , in vivo , biology , antibiotics , antibiotic resistance , gene , biochemistry

The dissemination of MBLs compromises effective use of many β-lactams in the treatment of patients with life-threatening bacterial infections. Predicted global increases in the prevalence of MBL-producing carbapenem-resistant Enterobacterales (CRE) are being realized, yielding infections that are untreatable with existing therapies including newly approved β-lactam/β-lactamase inhibitor combinations. Developing MBL inhibitors (MBLIs) now is essential to address the growing threat that MBL-producing CRE pose to patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research